Cambridge Cognition and ActiGraph Announce Partnership to Accelerate Adoption of Digital Measurements for Central Nervous System Trials
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce a new strategic partnership with ActiGraph, a leading provider of wearable technologies for clinical trials. The partnership will deliver a broad suite of assessments to provide a fully rounded view of mental and physical capabilities. With both companies holding leading positions in their respective markets, it is anticipated that the co-promotion planned under the agreement will support growth in market share in the future.
ActiGraph’s AccelerantTM partnership program is designed to advance the use of digital health technologies (DHTs) in clinical development by simplifying CROs’ and technology vendors’ access to raw data streams. As part of this strategic partnership, Cambridge Cognition and ActiGraph will combine their collective expertise in digital data collection to enhance assessment capabilities in CNS trials in areas where there is a large unmet need, such as schizophrenia and dementia.
Cambridge Cognition offers accurate and sensitive touch-screen and voice-based digital assessments of cognition and other brain health indicators that have been based on over 30 years of innovation and scientific validation. The Company’s suite of e-clinical technology solutions can be used at home or in-clinic, giving pharmaceutical companies and research institutions flexibility to reliably capture a broad range of important clinical measures.
As well as being leaders in the collection of clinical insights for clinical trials, both companies also lead in providing solutions for academic researchers, enabling hundreds of research projects each year. The companies’ technologies have been used together by top 20 pharmaceutical companies in clinical trials already. The combination of actigraphy data and brain health assessments may enable more accurate multi-modal digital biomarkers in the future.
Francesca Cormack, Chief Scientist, Cambridge Cognition, commented:
“CNS disorders are characterised by a host of heterogeneous symptoms which impact daily life, but that are often inadequately addressed by existing treatments. Our partnership with ActiGraph represents an exciting combination of expertise in objective digital measures of actigraphy, speech and cognition that will help accelerate the development of treatments for patients and improve efficiency in clinical trials.”
Christine Guo, Chief Scientific Officer, ActiGraph, commented:
"Digital health technologies give us the ability to collect data objectively during a patient’s everyday life. This is especially important in CNS disorders where conventional assessments are prone to subjective biases. We are excited about this partnership with Cambridge Cognition to provide advanced clinical insights to study teams conducting CNS trials.”
